A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT ID: NCT02954094

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients, age ≥18 years
2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included)

Exclusion Criteria

1\. Inability to provide written informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Target PharmaSolutions, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner University Medical Center

Phoenix, Arizona, United States

Site Status

University of Arkansas

Little Rock, Arkansas, United States

Site Status

University of Southern California/Norris Comprehensive Cancer Center

Los Angeles, California, United States

Site Status

Stanford University

Palo Alto, California, United States

Site Status

California Liver Research Institute

Pasadena, California, United States

Site Status

University of California-Davis

Sacramento, California, United States

Site Status

University of California

San Francisco, California, United States

Site Status

Georgetown University

Washington D.C., District of Columbia, United States

Site Status

Gastro Florida

Clearwater, Florida, United States

Site Status

University of Florida Hepatology Research at CTRB

Gainesville, Florida, United States

Site Status

University of Florida Health Gastroenterology

Jacksonville, Florida, United States

Site Status

Schiff Center for Liver Diseases/University of Miami

Miami, Florida, United States

Site Status

Tampa General Medical Group

Tampa, Florida, United States

Site Status

Piedmont Atlanta Hospital

Atlanta, Georgia, United States

Site Status

Piedmont Cancer Institute

Atlanta, Georgia, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

Northwestern University Division of Gastroenterology and Hepatology

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Tulane University

New Orleans, Louisiana, United States

Site Status

Mercy Medical Center, GI Research

Baltimore, Maryland, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Southern Therapy and Advanced Research (STAR) LLC

Jackson, Mississippi, United States

Site Status

Saint Louis University

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Rutgers-Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Site Status

Northwell Health - Center for Liver Diseases

Manhasset, New York, United States

Site Status

NYU Langone Health

New York, New York, United States

Site Status

Weill Cornell Medical College

New York, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Center for Liver Disease and Transplant at CMC

Charlotte, North Carolina, United States

Site Status

Providence Health & Services Cancer Clinical Trials

Portland, Oregon, United States

Site Status

Penn State Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Vanderbilt University Medical Center - GI Research Office

Nashville, Tennessee, United States

Site Status

Clinical Research Institute@ Methodist Dallas Medical Center

Dallas, Texas, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

Baylor Scott & White All Saints

Fort Worth, Texas, United States

Site Status

Research Specialists of Texas

Houston, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Bon Secours Liver Institute of Virginia

Richmond, Virginia, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

Wenatchee Valley Hospital & Clinics

Wenatchee, Washington, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

CHU de Nice - Hôpital L'Archet 2

Nice, , France

Site Status

Hôpitaux Universitaires Paris Centre

Paris, , France

Site Status

Universitätsklinikum Aachen

Aachen, , Germany

Site Status

Charité - Universitätsmedizin Berlin

Berlin, , Germany

Site Status

Universitätsklinikum Düsseldorf

Düsseldorf, , Germany

Site Status

Universitätsklinikum Frankfurt

Frankfurt, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Universitätsklinikum Leipzig

Leipzig, , Germany

Site Status

Universitätsklinikum Magdeburg

Magdeburg, , Germany

Site Status

Universitätsmedizin Mainz

Mainz, , Germany

Site Status

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, , Italy

Site Status

A.O.U.P. di Palermo

Palermo, , Italy

Site Status

Humanitas Mirasole IRCCS

Rozzano, , Italy

Site Status

IRCCS "Casa Sollievo della Sofferenza"

San Giovanni Rotondo, , Italy

Site Status

Hospital Puerta de Hierro Majadahonda

Madrid, , Spain

Site Status

Clínica Universidad de Navarra

Pamplona, , Spain

Site Status

Hospital Universitario Marques de Valdecilla

Santander, , Spain

Site Status

Hospital Universitario Virgen del Rocío

Seville, , Spain

Site Status

Hospital Universitario Politècnic La Fe

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States France Germany Italy Spain

References

Explore related publications, articles, or registry entries linked to this study.

Cabrera R, Singal AG, Colombo M, Kelley RK, Lee H, Mospan AR, Meyer T, Newell P, Parikh ND, Sangro B, Reddy KR, Watkins S, Zink RC, Di Bisceglie AM. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. Hepatol Commun. 2020 Dec 21;5(3):538-547. doi: 10.1002/hep4.1652. eCollection 2021 Mar.

Reference Type DERIVED
PMID: 33681685 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TARGET-HCC

Identifier Type: -

Identifier Source: org_study_id